Alas you are not [funny]. And evidently not rational in your thinking either.
Fact. RCE has collaborations in some form in place with a few entities, including US Dept. of Defence, which granted funding of US$2 million (approximately $3 million AUD to "accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacteria complications such as sepsis in military setting" (and oh look, FDA Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act – giving 327 fast track designation and 10 years of market exclusivity post approval).
That nice little grant would be (other) revenue on a typical P&L statement in case you are unaware. So would that nice little $6.75 million R&D tax kickback as well should you be unaware.
Now it also has collaboration of form with Etana, engaged by the Indonesian government to advancing public health by innovation. Oh yeah. Now you probably haven't heard Rykster, but PT Etana Biotechnologies (who you probably dismiss of inconsequence) in the past secured financing of undisclosed value (ooooh!!??) from Chinese investors that included two of Jack Ma’s capital investment funds.
So suggesting PAR might have capital inflow and revenue avenues beyond a capital raise is not stupid. Your usual sniping dismissal, is.
You must be very disappointed today Rykster, your baseless FUD clearly not working on the stock price. Try harder (I want some more cheap stock).
RCE Price at posting:
35.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)